Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
2019 CMS Medicare Payments: Proposed Changes and What They Mean for P&C Insurers
Several states in auto and workers’ compensation claims administration have adopted the Centers of Medicare and Medicaid Services’ (CMS) fee schedules and/or rules for payment of claims. The methodologies employed by CMS in provider billing and payment are typically either mandated by statute or become standards for appropriate billing and payment of claims. When Medicare adds new codes or proposes changes to fee schedules, Mitchell prepares for these changes by reviewing the proposed changes and how they could affect the Property and Casualty industry.
Genex Services Extends Care Continuum Through PCS Acquisition
Specialty network provider helps Genex expand and streamline its medical management services
Mitchell and Genex sign merger agreement that brings together leaders in medical compliance, cost containment and clinical solutions
Genex to become a new division, continuing to deliver industry leading clinical solutions
Before You Choose a PBM, do the Math
Cost is black & white Price alone isn’t. Your PBM must also control utilization or you’ll be seeing red.
Five Initial Evaluation Issues That May Delay Return to Work
When there’s a return to work delay, practitioners often look for problems that occurred during the course of treatment. However, as Mariellen Blue, Genex’s National Director of Case Management Services, tells us in today’s Inside Workers’ Comp, you may have to go back a little further in the recovery plan to find the answer. Check out the five reasons why the initial evaluation may be the culprit.
Business Insurance: Creams cut pain, but price is the rub
Topical creams are becoming part of the mix of pain treatment options as doctors look for alternatives to addictive opioids.